EGFR and cancer prognosis

RI Nicholson, JMW Gee, ME Harper - European journal of cancer, 2001 - Elsevier
Elevated levels of the epidermal growth factor receptor (EGFR), a growth-factor-receptor
tyrosine kinase, and/or its cognate ligands have been identified as a common component of …

Comparing antibody and small-molecule therapies for cancer

K Imai, A Takaoka - Nature Reviews Cancer, 2006 - nature.com
The'magic bullet'concept of specifically targeting cancer cells at the same time as sparing
normal tissues is now proven, as several monoclonal antibodies and targeted small …

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non–small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

U Gatzemeier, A Pluzanska, A Szczesna… - Journal of Clinical …, 2007 - ascopubs.org
Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …

The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.

N Prenzel, OM Fischer, S Streit, S Hart… - Endocrine-related …, 2001 - erc.bioscientifica.com
Homeostasis of multicellular organisms is critically dependent on the correct interpretation of
the plethora of signals which cells are exposed to during their lifespan. Various soluble …

The EGFR as a target for anticancer therapy—focus on cetuximab

J Baselga - European journal of cancer, 2001 - Elsevier
The anti-epidermal-growth-factor-receptor (EGFR) monoclonal antibody cetuximab
specifically binds to the EGFR with high affinity, blocking growth-factor binding, receptor …

Receptor tyrosine kinase signalling as a target for cancer intervention strategies.

E Zwick, J Bange, A Ullrich - Endocrine-related cancer, 2001 - erc.bioscientifica.com
In multicellular organisms, communication between individual cells is essential for the
regulation and coordination of complex cellular processes such as growth, differentiation …

Epidermal growth factor receptor inhibition strategies in oncology

PM Harari - Endocrine-related cancer, 2004 - erc.bioscientifica.com
Molecular targeting strategies for cancer therapy are distinct from conventional
chemotherapy and radiotherapy in their potential to provide increased tumor specificity. One …

Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1, 4]diazepine derivatives as potent EGFR/CDK2 …

A Belal, NM Abdel Gawad, ABM Mehany… - Journal of enzyme …, 2022 - Taylor & Francis
A new series of 1 H-pyrrole (6a–c, 8a–c), pyrrolo [3, 2-d] pyrimidines (9a–c) and pyrrolo [3, 2-
e][1, 4] diazepines (11a–c) were designed and synthesised. These compounds were …

Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and …

SM Huang, PM Harari - Clinical Cancer Research, 2000 - AACR
We have recently demonstrated that molecular blockade of the epidermal growth factor
receptor with the anti-epidermal growth factor receptor (EGFR) monoclonal antibody C225 …

Chlorotoxin, a scorpion‐derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin

SA Lyons, J O'Neal, H Sontheimer - Glia, 2002 - Wiley Online Library
Highly migratory neuroectodermal cells share a common embryonic origin with cells of the
central nervous system (CNS). They include enteric, parasympathetic, sympathoadrenal …